Source - LSE Non-Regulatory
RNS Number : 9185V
Ananda Developments PLC
11 July 2024
 

ANANDA DEVELOPMENTS PLC

("Ananda" or the "Company")

 

Investor Evening

 

Ananda Developments plc (AQSE: ANA), a company focused on becoming a leading provider of regulator approved CBD-based medicines for chronic inflammatory pain conditions, is pleased to announce its participation in "The Pub Test" Investor Evening. This event is co-hosted by the Aquis Exchange and InvestorHub and will take place on Wednesday, 17th July 2024 at Samuel Pepys, Stew Ln, London EC4V 3PT, starting at 6:00 PM.

 

The Company's CEO, Melissa Sturgess, will engage in a fireside conversation designed especially for private investors. This setting offers a unique opportunity for attendees to interact directly with company executives, ask questions, and network with fellow investors.

 

Ananda's CEO, Melissa Sturgess, commented: "We look forward to meeting and engaging with interested parties, shareholders, potential shareholders, and stakeholders. This event is a fantastic opportunity to share our vision and answer any questions investors may have."

 

All attendees will have the chance to network over drinks and a buffet.

 

To register for the event, please use the following link: https://events.humanitix.com/the-pub-test-or-london-july-4-2024

 

 For more information please contact:

InvestorHub

Engage with us directly at Ananda

Developments Investor Hub

 

Sign up at

https://investors.anandadevelopments.com/s/a66906

ANANDA DEVELOPMENTS PLC

Chief Executive Officer

Melissa Sturgess

Executive Director

Jeremy Sturgess-Smith

 

+44 (0)7463 686 497 ir@anandadevelopments.com

SP ANGEL CORPORATE FINANCE LLP

Corporate Finance

Richard Morrison

Caroline Rowe

 

+44 (0)20 3470 0470

Corporate Broking

Abigail Wayne

Rob Rees

 

 

Yellow Jersey PR

Charles Goodwin

Zara McKinlay

+44 (0)20 3004 9512

 

 

 

About Ananda Developments

Ananda is an AQSE-listed company whose ambition is to be a leading provider of cannabinoid-based medicines for the treatment of complex, chronic inflammatory pain conditions.

 

For further information on the Company visit https://anandadevelopments.com/ or sign up at

https://investors.anandadevelopments.com/s/a66906.

 

 

https://investors.anandadevelopments.com/link/8r6koP

 

 

END

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAEALXEFFLLEFA
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account. AJ Bell logo

Related Charts